Short­ly af­ter sell­ing Sier­ra to GSK, Stephen Dil­ly heads to en­zyme en­gi­neer Codex­is as new CEO

On Feb. 22, Stephen Dil­ly had no clear am­bi­tions of sell­ing Sier­ra On­col­o­gy to GSK. But that quick­ly changed over the sub­se­quent weeks, and since sell­ing the biotech for near­ly $2 bil­lion in the spring, he’s made a quick leap to an­oth­er com­pa­ny’s C-suite.

Dil­ly heads to Codex­is on Aug. 9 to take over as pres­i­dent and CEO of the en­zyme en­gi­neer­ing shop, where he’s been on the board since June 2020. The com­pa­ny dis­closed the news af­ter the clos­ing bell on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER